维持性血透期间使用依特卡肽与肾移植后甲状旁腺切除术发生率
该回顾性研究纳入2015至2022年在本中心接受肾移植的372例维持性血透患者,按移植前拟钙剂类型分组。结果显示,依特卡肽组移植后甲状旁腺切除术发生率显著高于西那卡塞组和无拟钙剂组,且与依特卡肽剂量相关,但长期移植物功能、移植物丢失和死亡率相似。
要点
- 移植前使用依特卡肽者甲状旁腺切除术发生率显著高于西那卡塞或未用拟钙剂者。
- 依特卡肽剂量≥10 mg者甲状旁腺切除术发生率高于<10 mg者。
- 依特卡肽组术后血钙峰值更高且甲状旁腺切除术实施更早。
核心结论
- 维持性血透期间使用依特卡肽与移植后早期甲状旁腺切除术发生率增加相关,且该风险高于西那卡塞或未使用拟钙剂者。
研究设计与样本
- 回顾性研究,纳入2015年1月1日至2022年12月12日在本机构接受肾移植且符合预设标准的维持性血透患者372例,年龄53岁(IQR 42-62岁)。
- 按移植前拟钙剂治疗类型分为依特卡肽组35例、西那卡塞组75例和无拟钙剂组262例。
主要发现
- 中位随访1064天(IQR 367-1658天)后,依特卡肽组、西那卡塞组和无拟钙剂组的甲状旁腺切除术发生率分别为29%、12%和1%(P < 0.001)。
- 调整年龄、性别和血透龄后,依特卡肽与甲状旁腺切除术发生率增加相关(HR 97.0,95%CI 19.1-493.9,P < 0.001)。
- 甲状旁腺切除术发生率与依特卡肽剂量相关:≥10 mg组为6/11(54.6%),<10 mg组为4/24(16.7%),P = 0.02。
- 与西那卡塞组相比,依特卡肽组术后血钙峰值更高(P < 0.001),甲状旁腺切除术实施更早(中位80天 vs 480天,P < 0.001)。
- 长期移植物功能、移植物丢失和死亡率在组间相似。
临床怎么用
- 对维持性血透且等待肾移植的患者,选择拟钙剂时需权衡移植后甲状旁腺切除术风险,依特卡肽相关风险较高。
- 移植前使用依特卡肽者,术后应关注血钙和iPTH变化,警惕需早期行甲状旁腺切除术的情况。
局限性
- 回顾性单中心研究,样本量有限,依特卡肽组仅35例。
- 原文未报告各组基线iPTH、钙磷水平等混杂因素的详细比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Etelcalcetide is an i.v. calcimimetic agent, effectively reducing parathyroid hormone levels in patients on maintenance hemodialysis (HD). The clinical impact of discontinuing etelcalcetide at the time of kidney transplantation is unknown. METHODS: We retrospectively reviewed all patients on HD meeting predefined criteria who received a kidney transplant at our institution between January 1, 2015, and December 12, 2022. The incidence of parathyroidectomy and the evolution of calcium, phosphate, and intact parathyroid hormone (iPTH) levels after transplantation was analyzed according to the type of calcimimetic treatment before transplantation (cinacalcet vs. etelcalcetide vs. none). RESULTS: Overall, 372 patients (aged 53 years; interquartile range [IQR]: 42-62 years) were included. At the time of transplantation, 35, 75, and 262 patients were under etelcalcetide, cinacalcet, or no calcimimetic, respectively. After 1064 (IQR: 367-1658) days, the incidences of parathyroidectomy in the etelcalcetide, cinacalcet, no calcimimetic groups were 29%, 12%, and 1%, respectively (P < 0.001). Etelcalcetide was associated with an increased incidence of parathyroidectomy after adjustment for age, sex, and HD vintage (hazard ratio [HR]: 97.0, 95% confidence interval [CI]: 19.1-493.9, P < 0.001). The incidence of parathyroidectomy was related to etelcalcetide dosage (6/11 [54.6%] in patients with ≥ 10 mg vs. 4/24 [16.7%] in patients with < 10 mg, P = 0.02). Moreover, peak calcium levels were higher (P < 0.001) and parathyroidectomy was performed earlier (median 80 vs. 480 days, P < 0.001) in the etelcalcetide compared with the cinacalcet group. Long-term graft function, graft loss, and mortality were similar. CONCLUSION: Etelcalcetide use during maintenance HD is associated with an increased incidence of early parathyroidectomy after transplantation compared to cinacalcet or no calcimimetic.
引用
- Delaey P, Devresse A, Morelle J, et al. Etelcalcetide use During Maintenance Hemodialysis and Incidence of Parathyroidectomy After Kidney Transplantation. Kidney Int Rep. 2024. PMID: 39081745. doi:10.1016/j.ekir.2024.04.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。